Severine Beaudreuil

Dr. Severine Beaudreuil


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
SBSeverine Beaudreuil
Severine Beaudreuil
HLHans-Kristian Lorenzo
Hans-Kristian Lorenzo
MEMichelle Elias
Michelle Elias
EOErika Nnang Obada
Erika Nnang Obada
BCBernard Charpentier
Bernard Charpentier
ADAntoine Durrbach
Antoine Durrbach
Focal segmental glomerulosclerosis (FSGS) is a frequent glomerular kidney disease that is revealed by proteinuria or even nephrotic syndrome. A diagnosis can be established from a kidney biopsy that shows focal and segmental glomerulosclerosis. This histopathological lesion may be caused by a primary podocyte injury (idiopathic FSGS) but is also associated with other pathologies (secondary FSGS). The first-line treatment for idiopathic FSGS with nephrotic syndrome is a prolonged course of corticosteroids. However, steroid resistance or steroid dependence is frequent, and despite intensified immunosuppressive treatment, FSGS can lead to end-stage renal failure. In addition, in some cases, FSGS can recur on a graft after kidney transplantation: an unidentified circulating factor may be implicated. Understanding of its physiopathology is unclear, and it remains an important challenge for the scientific community to identify a specific diagnostic biomarker and to develop specific therapeutics. This study reviews the treatment of primary FSGS and the recurrence of FSGS after kidney transplantation in adults.

6 March 2017 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
MEMichelle Elias
Michelle Elias
ENErika Nnang‐Obada
Erika Nnang‐Obada
BCBernard Charpentier
Bernard Charpentier
ADAntoine Durrbach
Antoine Durrbach
SBSeverine Beaudreuil
Severine Beaudreuil

21 September 2022 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
VFValentine Forté
Valentine Forté
SNSophie Novelli
Sophie Novelli
MZMohamad Zaidan
Mohamad Zaidan
RSRenaud Snanoudj
Renaud Snanoudj
CVChristian Verger
Christian Verger
SBSeverine Beaudreuil
Severine Beaudreuil
Background: Previous studies have reported that polymicrobial peritonitis in peritoneal dialysis (PD) is associated with poor outcomes, but recent data from European cohorts are scarce. Methods: We included from the French Language Peritoneal Dialysis Registry all patients ≥18 years of age who started PD between January 2014 and November 2020. We compared microbiology and patient characteristics associated with mono- and polymicrobial peritonitis. We assessed patient outcomes after a first polymicrobial peritonitis using survival analysis with competing events. We differentiated microorganisms isolated from dialysis effluent as enteric or non-enteric pathogens. Results: A total of 8848 patients contributed 13 023 patient-years of follow-up and 3348 culture-positive peritonitis episodes, including 251 polymicrobial ones. This corresponded to rates of 0.32 and 0.02 episodes/patient-year, respectively. For most patients (72%) who experienced polymicrobial peritonitis, this was their first peritonitis episode. Enteric pathogens were more frequently isolated in polymicrobial than in monomicrobial peritonitis (57 versus 44%; P < .001). In both cases of peritonitis with and without enteric pathogens, the polymicrobial versus monomicrobial character of the peritonitis was not associated with mortality in patients who did not switch to haemodialysis {adjusted cause-specific hazard ratio [acsHR] 1.2 [95% confidence interval (CI) 0.3–5.0], P = .78 and 1.1 [95% CI 0.7–1.8], P = .73, respectively}. However, the risks of death and switch to haemodialysis were higher for monomicrobial peritonitis with enteric pathogens compared with those without [acsHR 1.3 (95% CI 1.1–1.7), P = .02 and 1.9 (95% CI 1.5–2.4), P < .0001, respectively]. Conclusion: Isolation of enteric pathogens, rather than the polymicrobial character of the peritonitis, is associated with poorer outcomes.

1 January 2015 in Saudi Journal of Kidney Diseases and Transplantation
Verified
Journal Article
Open access
PDF file
Nassim KamarNassim Kamar
Nassim Kamar
HHHadia Hebibi
Hadia Hebibi
HWHugo Weclawiak
Hugo Weclawiak
Lionel ROSTAINGLionel ROSTAING
Lionel ROSTAING
SBSeverine Beaudreuil
Severine Beaudreuil
ADAntoine Durrbach
Antoine Durrbach
Few studies have reported the use of double-filtration plasmapheresis (DFPP) in antibody-incompatible kidney transplantation. To assess the efficiency and tolerability of DFPP, we prospectively studied four chronic hemodialysis patients from two centers undergoing antibody-incompatible kidney transplantation. DFPP was used for ABO-incompatible transplantation (n = 1), for high human leukocyte antigen (HLA) immunization levels (n = 2) or for the presence of a donor-specific antibody (DSA) against a potential living donor (n = 1). In all the patients, the DFPP program was discontinued because of the adverse effects. Low blood pressure occurred during the first hour of the session in all the patients. A significant loss of plasma proteins, clotting factors and immunoglobulins also occurred during this treatment. In addition, fistula thrombosis was diagnosed in two patients. Three patients experienced gastrointestinal symptoms. The DFPP reduced the titers of the anti-B antibodies and reduced the levels of DSA in one patient, but had no effect on anti-HLA antibodies in the remaining two patients. Our study highlights the non-tolerability and poor efficacy of DFPP prior to antibody-incompatible kidney transplantation that limit its extensive use in the desensitization protocols.

28 January 2022 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
HHHEBIBI HEDIA
HEBIBI HEDIA
MEMarvin Edeas
Marvin Edeas
LCLaure Cornillac
Laure Cornillac
SBSeverine Beaudreuil
Severine Beaudreuil
JAJedjiga Achiche
Jedjiga Achiche
BCBernard Canaud
Bernard Canaud
Background: Due to their immunocompromised conditions, hemodialysis (HD) patients are at high risk of being infected with SARS-CoV-2 with poor clinical outcomes. We explored safety, efficacy and variability factors associated with vaccine immune response in these patients. Methods: From 18 January to 30 April 2021, 87 HD patients were enrolled in this study and subdivided in two sub-groups: SARS-CoV-2 positive prior to vaccination and naïve patients. The vaccination protocol included two intramuscular shots of the mRNA vaccine at a 28-day interval. The vaccine response was evaluated one month after the first and second shots by measuring anti-S antibody titers. Findings: 44% of the patients studied, were women; median age was 58 years. One month after the first shot, 64.3% of patients had anti-S antibody titers < 50 U/mL while 96.5% had anti-S antibody titers > 250 U/mL one month after the second shot. We show that the anti-SARS-CoV-2 spike mRNA vaccine elicits a great tolerability in HD patients. Importantlly, the vaccine response is characterized by a higher rate of seroconversion than conventional vaccination, as we have shown for the hepatitis B vaccine. We highlight two major factors of variability of the vaccine response. First, pre-exposure to SARS-CoV-2 boosts humoral response, as 95% of SARS-CoV-2 positive patients developed anti-S antibody titers > 250 U/L just after the first shot. Secondly, on the contrary fluid overload strikingly appears, limiting the vaccine response, as 84% of HD patients with fluid overload elicit lower anti-S antibody titers after the first shot. Interpretation: Our findings show that the immunogenic profile induced by mRNA vaccines in HD patients represents a promising a protective strategy that is associated with greater tolerability. Fluid overload may be considered as a novel factor that hinders the immune response in HD patients and further studies will be needed to investigate this working hypothesis.

1 January 2017 in Bulletin de l'Académie Nationale de Médecine
Verified
Journal Article
Closed access
SBSeverine Beaudreuil
Severine Beaudreuil
ADAntoine DURRBACH
Antoine DURRBACH